Good Distribution Practice (GDP) for Medicines Explained

Good Distribution Practice (GDP) is the part of quality assurance that ensures medicines keep their quality and integrity as they move through the supply chain, from the manufacturer's warehouse to the pharmacy or hospital. It covers storage, transport, documentation and the controls that keep falsified medicines out of the legitimate chain.

A product made under perfect GMP can still be damaged by a hot loading bay, an unqualified van or a missed temperature alarm. For distributors, 3PL warehouses and importers in the GCC and India, GDP is a licensing expectation and a daily operational discipline.

The main GDP guidance documents

The most widely used reference is the EU Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C 343/01). Its chapters cover quality management, personnel, premises and equipment, documentation, operations, complaints and returns, suspected falsified medicines and recalls, outsourced activities, self-inspections, transportation and brokers.

The World Health Organization publishes good storage and distribution practices guidance for medical products in its Technical Report Series, which many national regulators use as a basis for their own rules. In the GCC, regulators such as the SFDA in Saudi Arabia and the relevant UAE health authorities publish their own storage and distribution requirements and licence warehouses and distributors. In India, CDSCO has issued GDP guidance, and wholesale licences are granted by state drug control authorities.

Requirements, licence types and inspection practice differ between authorities, and some have changed in recent years. Confirm the current rules with the authority that licenses your site before writing or updating procedures.

Key GDP requirements and practical controls

Returns and falsified medicines

Returned medicines should only go back to saleable stock after a documented assessment, including evidence that storage conditions were maintained while the product was outside your control. Suspected falsified medicines must be physically segregated and reported to the authority and, where appropriate, the marketing authorisation holder, as your local rules require.

Temperature mapping and monitoring

Temperature mapping shows how temperature varies across a storage area, identifying hot and cold spots near doors, roofs, racks and air handling units. EU GDP expects mapping before a storage area is used, under representative conditions, and repeated according to risk or after significant modifications.

In the GCC, mapping should include summer conditions, when outside temperatures place heavy loads on cooling systems, as well as cooler months. Loading docks, mezzanine levels and areas under metal roofs deserve particular attention. The principles behind qualifying equipment such as cold rooms are covered in IQ, OQ and PQ qualification explained.

Cold chain for 2-8 °C products

Vaccines, insulins and many biologics must be kept at 2-8 °C. Key controls include:

• qualified cold rooms and pharmaceutical refrigerators with continuous monitoring and alarms
• validated insulated shippers or active temperature-controlled containers, with packing instructions for each season
• calibrated data loggers placed in the shipment where the risk is highest
• minimal time on open loading docks, with pre-cooled vehicles where used
• a defined excursion procedure: quarantine, data review, assessment against stability data from the marketing authorisation holder, and a documented decision

Transport in GCC heat

Products labelled for storage below 25 °C or 30 °C are also at risk during summer transport in the Gulf, where vehicle interiors can far exceed ambient temperature. Controlled room temperature shipments may need active temperature control or qualified passive packaging, not just a covered vehicle.

Practical measures include route risk assessments, deliveries outside the hottest hours where possible, vehicle temperature mapping, and clear driver instructions on stops, door openings and breakdowns. Last-mile deliveries are often the weakest link.

Worked example: a Dubai distributor qualifying a 3PL

A pharmaceutical distributor in Dubai plans to move storage of both 15-25 °C and 2-8 °C products to a third-party logistics (3PL) warehouse. Under the outsourcing principles of GDP, the distributor remains responsible for the activities it contracts out.

1. Licence check: QA confirms the 3PL holds the licences required by the relevant authority for storing medicines and checks the scope covers cold chain storage.
2. Questionnaire and document review: the 3PL provides its quality manual, SOP index, organisation chart, training records and recent self-inspection reports.
3. On-site audit: the auditor reviews mapping reports for ambient and cold rooms, including summer data, alarm records and response times, calibration certificates, pest control, segregation of quarantine and rejected stock, and vehicle qualification.
4. Findings: alarm escalation outside working hours relies on a single phone number, and the last cold room mapping predates a racking change. The 3PL agrees CAPA: a tiered call-out list and remapping.
5. Quality agreement: both parties sign a written agreement defining responsibilities for receipt, storage, excursions, returns, recalls, complaints, change notification, record retention and audit rights.
6. Ongoing oversight: the distributor sets performance indicators such as excursions, picking errors and on-time CAPA closure, and schedules periodic reviews and audits.

The value came from closing the findings before stock moved, and from an agreement that leaves no responsibility unassigned.

Common mistakes

• Mapping a warehouse once in winter and never again.
• Placing monitoring probes for convenience rather than at mapped hot and cold spots.
• Returning stock to saleable inventory without evidence of storage conditions.
• Treating a courier or 3PL as fully responsible once a contract is signed.
• Using one packing configuration all year in a climate with extreme seasonal swings.
• Releasing products after an excursion without product-specific stability data.
• Testing alarms during the day but never out of hours.

Key takeaway: GDP protects everything GMP achieved. Map your storage, qualify your transport, control your contractors and treat every temperature excursion as a quality decision backed by data.

Frequently Asked Questions

What is the difference between GMP and GDP?

GMP covers how medicines are manufactured and controlled so that each batch meets its quality standards. GDP covers what happens afterwards, during storage, transport and distribution through the supply chain. Both aim to protect patients, and the two overlap where manufacturers store and ship their own products. Distributors and 3PL warehouses mainly follow GDP requirements.

Is temperature mapping mandatory under GDP?

EU GDP expects an initial temperature mapping exercise of storage areas before use, under representative conditions, with monitoring equipment placed according to the results. Mapping should be repeated based on risk or after significant changes. Other regulators have similar expectations, but the details vary, so confirm what your licensing authority requires.

What should happen after a cold chain excursion?

Quarantine the affected stock, retrieve and review the temperature data, and record the duration and extent of the excursion. Then assess the impact using product-specific stability information, usually from the marketing authorisation holder. The release or rejection decision should be documented by authorised quality personnel, and the root cause investigated through your deviation and CAPA process.

Who needs a GDP licence in the UAE or Saudi Arabia?

Organisations that store, import or distribute medicines generally need a licence from the relevant health authority, and their premises are usually inspected. The exact licence types, conditions and responsible authority differ between the UAE, Saudi Arabia and other GCC states, and have changed over time. Confirm current requirements directly with the regulator before starting operations.

What is a quality agreement with a 3PL?

A quality agreement is a written contract that defines GDP responsibilities between a distributor and its logistics provider. It typically covers receipt, storage conditions, excursion handling, returns, recalls, complaints, change notification, records, subcontracting and audit rights. It ensures that every GDP task has a named owner and that the contract giver can verify compliance.

Next steps

If you work in pharmaceutical supply chain, QA or regulatory roles in the Gulf, our Regulatory Affairs for Pharma & Medical Devices in the GCC course and Internal Auditing & Audit Readiness Essentials are good next steps. For related reading, see GMP vs cGMP, pharmaceutical product registration in the UAE and Saudi Arabia and IQ, OQ and PQ qualification explained. You can also speak to a counsellor.